Search Videos and More
News
Dana-Farber Researchers Find Less Treatment May be More in Mantle Cell Lymphoma
For a long time, the standard treatment for younger patients with newly diagnosed mantle cell lymphoma involved intensive chemotherapy, called induction therapy, followed by autologous stem cell transplant (ASCT, where the patient’s own stem cells are used), followed by maintenance therapy to help keep the cancer from coming back.
News
TILs: What Are They and How Are They Used in Cancer Treatment?
Tumor-infiltrating lymphocyte, or TIL, therapy uses a patient’s own immune system T cells to fight cancer.
News
Years of Research Help Forge a New Path in Hodgkin Lymphoma Treatment
Medical advances tend to unfold slowly over many years, fueled by successive clinical studies that build upon each other and together provide the evidence needed to change patient care.
News
Continuing to Advance the Standard of Care for Newly Diagnosed and Relapsed/Refractory Multiple Myeloma
Dana-Farber Cancer Institute continues to lead the way in clinical research to further improve longevity and quality of life for our patients with multiple myeloma (MM).
News
Novel Approaches in Waldenström's Macroglobulinemia
Dana-Farber Cancer Institute researchers will present important research studies during the 2025 ASCO Genitourinary (GU) Cancers Symposium, on February 13-15, 2025, in San Francisco, Calif.
News
Dana-Farber Researchers to Present Key Transplant and Cellular Therapy Studies at 2025 Tandem Meetings
Dana-Farber Cancer Institute researchers presented key research studies at the 2025 Tandem Meetings, the premier conference in hematopoietic cell transplantation (HCT) and cellular therapy.
News
What is a Menin Inhibitor?
Menin, a protein located in the nucleus of various human cell types, often functions as a tumor suppressor by inhibiting excessive cell growth and division.
News
Dana-Farber Investigators Pinpoint Keys to Cell Therapy Response for Leukemia
Dana-Farber Cancer Institute researchers have identified factors that determine whether donor lymphocyte infusion (DLI), a standard therapy for patients with acute myeloid leukemia (AML) who have relapsed after allogenic hematopoietic stem cell transplant, will successfully move the patient into remission.
Symposium
2024 ASH Highlights
Review presentations and information shared by Dana-Farber physician-scientists at the 66th American Society of Hematology Annual Meeting & Exposition in San Diego on Dec. 1-10th, 2024.
Symposium
American Society of Hematology 2025
Review video recaps of presentations and information shared by Dana-Farber physician-scientists at the 67th American Society of Hematology Annual Meeting & Exposition in Orlando, FL on Dec. 5th-9th, 2025.
News
Rapid Blood Cancer Diagnostic Could Speed Decisions and Save Lives
Researchers at Dana-Farber Cancer Institute have created a CRISPR-based rapid molecular diagnostic for two forms of leukemia that are driven by mutations that involve gene fusions.
News
Researchers Devise Novel Solution to Preventing Relapse after CAR T-cell Therapy
Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.